Advances in Clinical and Experimental Medicine

Title abbreviation: Adv Clin Exp Med
JCR Impact Factor (IF) – 2.1 (5-Year IF – 2.0)
Journal Citation Indicator (JCI) (2023) – 0.4
Scopus CiteScore – 3.7 (CiteScore Tracker 3.8)
Index Copernicus  – 171.00; MNiSW – 70 pts

ISSN 1899–5276 (print)
ISSN 2451-2680 (online)
Periodicity – monthly

Download original text (EN)

Advances in Clinical and Experimental Medicine

2019, vol. 28, nr 6, June, p. 759–763

doi: 10.17219/acem/92012

Publication type: original article

Language: English

Download citation:

  • BIBTEX (JabRef, Mendeley)
  • RIS (Papers, Reference Manager, RefWorks, Zotero)

VEGF serum concentration and irreversible bronchoconstriction in adult asthmatics

Krzysztof Gomułka1,A,B,D, Jerzy Liebhart1,F, Urszula Gładysz2,C, Wojciech Mędrala1,E

1 Department of Internal Medicine and Allergology, Wroclaw Medical University, Poland

2 Institute of Informatics, University of Wrocław, Poland

Abstract

Background. Vascular endothelial growth factor (VEGF) is an angiogenic, heparin-binding glycoprotein playing an important role in the pathogenesis of many diseases and disorders, including asthma. It has been reported that increased VEGF serum concentration is a biomarker of neovascularization, which could suggest that higher VEGF expression may be relevant to asthmatics with airway remodeling and irreversible bronchoconstriction.
Objectives. The aim of this study was to assess the possible association between VEGF serum concentration and irreversible bronchoconstriction in adult patients with a diagnosis of asthma.
Material and Methods. This study involved 82 adult patients with asthma (42 persons with and 40 persons without irreversible bronchoconstriction) and 40 healthy adult controls. Vascular endothelial growth factor serum concentration was analyzed using enzyme-linked immunosorbent assay (ELISA).
Results. Vascular endothelial growth factor serum concentration in patients with asthma was higher than in healthy controls (p = 0.0131), particularly in those from the subgroup of irreversible bronchoconstriction (p = 0.0133). The rising tendency was confirmed using the Kruskal–Wallis rank sum test that showed a significant difference (p = 0.0374) in VEGF values among the 3 groups examined: healthy controls (Me = 246.6 pg/mL), asthmatics with reversible bronchoconstriction (Me = 288.6 pg/mL) and asthmatics with irreversible bronchoconstriction (Me = 340.6 pg/mL). However, the direct comparison between the 2 asthmatics groups (reversible vs irreversible bronchoconstriction) did not show a statistically significant difference (p = 0.5521).
Conclusion. Increased VEGF serum concentration is characteristic of patients with asthma, especially those with irreversible bronchoconstriction.

Key words

asthma, vascular endothelial growth factor, remodeling, bronchoconstriction

References (30)

  1. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med. 2003;9(6):669–676.
  2. Gomułka K, Liebhart J. Vascular endothelial growth factor: Structure, function and role in airways inflammation and the clinical course of asthma [in Polish]. Pneumonol Alergol Pol. 2009;77(6):549–553.
  3. Gover-Proaktor A, Granot G, Shapira S, et al. Ponatinib reduces viability, migration, and functionality of human endothelial cells. Leuk Lymphoma. 2017;58(6):1455–1467.
  4. Yamamoto H, Rundqvist H, Branco C, Johnson RS. Autocrine VEGF isoforms differentially regulate endothelial cell behavior. Front Cell Dev Biol. 2016;4:99.
  5. Xin H, Zhong C, Nudleman E, Ferrara N. Evidence for pro-angiogenic functions of VEGF-Ax. Cell. 2016;167(1):275–284.
  6. Campochiaro PA, Aiello LP, Rosenfeld PJ. Anti-vascular endothelial growth factor agents in the treatment of retinal disease: From bench to bedside. Ophthalmology. 2016;123(10S):78–88.
  7. Paradowska-Gorycka A, Pawlik A, Romanowska-Prochnicka K, et al. Relationship between VEGF gene polymorphisms and serum VEGF protein levels in patients with rheumatoid arthritis. PLoS One. 2016;11(8):e0160769.
  8. Heitrich M, García DM, Stoyanoff TR, Rodríguez JP, Todaro JS, Aguirre MV. Erythropoietin attenuates renal and pulmonary injury in polymicrobial induced-sepsis through EPO-R, VEGF and VEGF-R2 modulation. Biomed Pharmacother. 2016;82:606–613.
  9. Bulysheva AA, Hargrave B, Burcus N, Lundberg CL, Murray L, Heller RR. Vascular endothelial growth factor-A gene electrotransfer promotes angiogenesis in a porcine model of cardiac ischemia. Gene Ther. 2016;23(8–9):649–656.
  10. García-Lucio J, Argemi G, Tura-Ceide O, et al. Gene expression profile of angiogenic factors in pulmonary arteries in COPD: Relationship with vascular remodeling. Am J Physiol Lung Cell Mol Physiol. 2016;310(7):583–592.
  11. Wheler JJ, Janku F, Naing A, et al. TP53 alterations correlate with response to VEGF/VEGFR inhibitors: Implications for targeted therapeutics. Mol Cancer Ther. 2016;15(10):2475–2485.
  12. Wojtukiewicz MZ, Sierko E, Skalij P, et al. Granulocyte-colony stimulating factor receptor, tissue factor, and VEGF-R bound VEGF in human breast cancer in loco. Adv Clin Exp Med. 2016;25(3):505–511.
  13. Grzela K, Litwiniuk M, Krejner A, Zagorska W, Grzela T. Increased angiogenic factors in exhaled breath condensate of children with severe asthma: New markers of disease progression? Respir Med. 2016;118:119–121.
  14. Lee KY, Lee KS, Park SJ, et al. Clinical significance of plasma and serum vascular endothelial growth factor in asthma. J Asthma. 2008;45(9):735–739.
  15. Lachheb J, Chelbi H, Dhifallah IB, et al. Association of vascular endothelial growth factor polymorphisms with asthma in Tunisian children. Gene Regul Syst Bio. 2008;2:89–96.
  16. Pei QM, Jiang P, Yang M, et al. Upregulation of a disintegrin and metalloproteinase-33 by VEGF in human airway smooth muscle cells: Implications for asthma. Cell Cycle. 2016;15(20):2819–2826.
  17. Sharma S, Murphy AJ, Soto-Quiros ME, et al. Association of VEGF polymorphisms with childhood asthma, lung function and airway responsiveness. Eur Respir J. 2009;33(6):1287–1294.
  18. Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS, Dvorak HF. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science. 1983;219(4587):983–985.
  19. Ferrara N, Henzel WJ. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem Biophys Res Commun. 1989;161(2):851–858.
  20. Czarniakowska-Bołtuć M, Ziętkowski Z, Bodzenta-Łukaszyk A. Rola wybranych czynników wzrostowych w astmie. Alergia Astma Immunol. 2012;17:172–179.
  21. Meyer N, Akdis CA. Vascular endothelial growth factor as a key inducer of angiogenesis in the asthmatic airways. Curr Allergy Asthma Rep. 2013;13(1):1–9.
  22. Li X, Wilson JW. Increased vascularity in the bronchial mucosa in mild asthma. Am J Respir Crit Care Med. 1997;156(1):229–233.
  23. Lee C, Ma B, Takyar S, et al. Studies of vascular endothelial growth factor in asthma and chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2011;8(6):512–515.
  24. Koczy-Baron E, Kasperska-Zając A. Rola naczyniowo-śródbłonkowego czynnika wzrostu w procesach zapalnych. Postepy Hig Med Dosw (Online). 2014;68:57–65.
  25. Barbato A, Turato G, Baraldo S, et al. Airway inflammation in childhood asthma. Am J Respir Crit Care Med. 2003;168(7):798–803.
  26. Abdel-Rahman AM, el-Sahrigy SA, Bakr SI. A comparative study of two angiogenic factors: Vascular endothelial growth factor and angiogenin in induced sputum from asthmatic children in acute attack. Chest. 2006;129(2):266–271.
  27. Asai K, Kanazawa H, Kamoi H, Shiraishi S, Hirata K, Yoshikawa J. Increased levels of vascular endothelial growth factor in induced sputum in asthmatic patients. Clin Exp Allergy. 2003;33(5):595–599.
  28. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention 2017 (revision). https://ginasthma.org/wms-GINA-2017-main-report-tracked-changes-for-archive.pdf
  29. Chebib R, Verlingue L, Cozic N, et al. Angiogenesis inhibition in the second-line treatment of metastatic colorectal cancer: A systematic review and pooled analysis. Semin Oncol. 2017;44(2):114–128.
  30. Evans J, Virgili G. Anti-VEGF drugs: Evidence for effectiveness. Community Eye Health. 2014;27(87):48.
© Wroclaw Medical University